You are using an outdated browser. Please upgrade your browser to improve your experience.

cemiplimab

Ligand Summary
Description
Cemiplimab-rwlc is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Synonyms & Links
DrugCentral: 5317
LyCHI:  cemiplimab


loading...
Target Activities